All In Biotech

Investigational drug · Phase 2

YK012

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Systemic Lupus Erythematosus (SLE), B-cell Acute Lymphoblastic Leukemia.

Phase 2

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

6

Any phase or sponsor naming "YK012"

First trial start

2024

Sep 25, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "YK012", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Systemic Lupus Erythematosus (SLE)
  • B-cell Acute Lymphoblastic Leukemia

Approved drugs for the same conditions: Acute lymphoblastic leukemia · Lupus (SLE) · Hematology and blood cancers · Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "YK012" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Systemic Lupus Erythematosus (SLE)

  • hUC-MSCsmesenchymal stem cells, MSCPhase 38 trials

    Shenzhen Wingor Biotechnology Co., Ltd. · Knee Osteoarthritis, Crohn&Amp;#39;s, Crohn&Amp;#39;s Disease (CD)

  • EnpatoranM5049, M5049 dosePhase 35 trials

    EMD Serono Research & Development Institute, Inc. · Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus

  • LitifilimabBIIB059Phase 35 trials

    Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic

  • SCTC21CPhase 34 trials

    Sinocelltech Ltd. · IgA Nephropathy, Multiple Myeloma (MM), Systemic Lupus Erythematosus (SLE)

  • SG301Phase 33 trials

    Hangzhou Sumgen Biotech Co., Ltd. · Systemic Lupus Erythematosus (SLE), Relapsed/Refractory Multiple Myeloma, Antibody Mediated Rejection

  • Descartes-08Phase 24 trials

    Cartesian Therapeutics · Myasthenia Gravis, Generalized, Childhood-onset Systemic Lupus Erythematous, ANCA-Associated Vasculitis (AAV)

  • ESG206ESG206-2Phase 23 trials

    Shanghai Escugen Biotechnology Co., Ltd · Systemic Lupus Erythematosus (SLE), Immune Thrombocytopenia (ITP), Primary Sjögren Syndrome

  • BCMA-CD19-IL-15Phase 22 trials

    iCell Gene Therapeutics · Inflammatory Bowel Diseases (IBD), Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.